from the laboratory bench to the patient's bedside /
First Statement of Responsibility
by Ibis Sánchez-Serrano.
EDITION STATEMENT
Edition Statement
1st ed.
.PUBLICATION, DISTRIBUTION, ETC
Place of Publication, Distribution, etc.
Boston :
Name of Publisher, Distributor, etc.
Elsevier,
Date of Publication, Distribution, etc.
2011.
PHYSICAL DESCRIPTION
Specific Material Designation and Extent of Item
xxiii, 271 p. :
Other Physical Details
ill. ;
Dimensions
24 cm
SERIES
Series Title
Elsevier insights
INTERNAL BIBLIOGRAPHIES/INDEXES NOTE
Text of Note
Includes bibliographical references.
CONTENTS NOTE
Text of Note
Pt. I. The global health care crisis. 1. The world's health care crisis : the United States' leadership -- 2. The health care crisis in other parts of the world -- Pt. II. Understanding the biopharmaceutical business. 3. A brief commercial history of the biopharmaceutical industry up to the year 2000 -- 4. The biopharmaceutical industry in the twenty-first century : titanic challenges ahead -- 5. Understanding research and development and marketing in a biopharmaceutical company -- 6. The pharmaceutical regulators -- Pt. III. The complexity of innovation. 7. The academia-industry relationship -- 8. Translating academic innovation into health care products -- 9. The biotechnology world and its challenges -- 10. Causes of the pharmaceutical crisis -- Part IV. Morality and duty on a lonely planet. 11. Wealth versus poverty -- 12. Social responsibility, governmental role, and nongovernmental organizations -- Pt. V. Reinventing research and development. 13. Time for reorganization -- Conclusion. Future trends.
0
SUMMARY OR ABSTRACT
Text of Note
At present, human society is facing a health care crisis that is affecting patients worldwide. In the United States, it is generally believed that the major problem is lack of affordable access to health care (i.e. health insurance). This book takes an unprecedented approach to address this issue by proposing that the major problem is not lack of affordable access to health care per se, but lack of access to better, safer, and more affordable medicines. The latter problem is present not only in the United States and the developing world but also in countries with socialized health care systems, such as Europe and the rest of the industrialized world. This book provides a comparative analysis of the health care systems throughout the world and also examines the biotechnology and pharmaceutical industries. Examines the health care structure of the United States, Europe, and the third world, both separately and comparatively offers primary source insight through in-depth interviews with pharmaceutical and health care industry leaders from around the world. Carefully explains, in clear terms, the intricacies of the health care and pharmaceutical system and how these intricacies have led to the current crisis. Offers concrete, comprehensive solutions to the health care crisis.